| Quinacrine-Capecitabine Combinatorial Therapy for Advanced Stage Colorectal Adenocarcinoma | Quinacrine-Capecitabine Combinatorial Therapy for Advanced Stage Colorectal Adenocarcinoma:A Phase I/II Investigator-Initiated Clinical Trial | NCT01844076 |
| Erlotinib Hydrochloride and Quinacrine Dihydrochloride in Stage IIIB-IV Non-Small Cell Lung Cancer | A Phase I Study of Erlotinib in Combination With Quinacrine in Patients With Advanced Non-Small-Cell Lung Cancer | NCT01839955 |
| Quinacrine Treatment in Patients With Androgen-Independent Prostate Cancer | An Open-Label, Phase II Safety, Tolerability, Drug Level and Efficacy Trial of Quinacrine in Patients With Androgen-Independent Metastatic Prostate Cancer | NCT00417274 |
| Treatment of Advanced Renal Cell Carcinoma With Quinacrine | An Open-label, Fixed-dose, Clinical Study of Quinacrine Safety and Efficacy in the Treatment of Advanced Renal Cell Carcinoma | NCT00574483 |
| PRION-1: Quinacrine for human prion disease. A partially randomised patient preference trial to evaluate the activity and safety of quinacrine in human prion disease | | ISRCTN06722585 |
| CJD (Creutzfeldt-Jakob Disease) Quinacrine Study | Novel Therapeutics For Prion Diseases: A Randomized, Double-blinded, Placebo-controlled Study of the Efficacy of Quinacrine in the Treatment of Sporadic Creutzfeldt-Jakob Disease | NCT00183092 |
